Sana Biotechnology, Inc. (SANA) shareholders
Close on Nov 18, 2026Market cap $553.82MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert Nelsen Joint filing with ARCH Venture Fund IX, L.P. (15.30%), ARCH Venture Fund IX Overage, L.P. (15.30%) and 12 more | 46,173,125 | 15.40% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (12.50%) | 37,293,854 | 12.50% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (14.21%) | 31,609,175 | 14.21% | 13G (passive) amendment | Nov 12, 2024 |
| Noubar B. Afeyan, Ph.D Joint filing with Flagship Pioneering, Inc. (8.10%) | 25,583,551 | 13.00% | 13G (passive) amendment | Dec 31, 2023 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (6.30%), Rajeev Shah (6.30%) and 1 more | 18,750,000 | 6.30% | 13G (passive) | May 14, 2026 |
| BlackRock, Inc. | 13,643,304 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SANA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 37,429,515 | 12.50% | $130.63M | −769 | 0.01% |
| Flagship Pioneering Inc. | 25,001,856 | 8.35% | $87.26M | – | 5.67% |
| Ra Capital Management, L.P. | 18,750,000 | 6.26% | $65.44M | New | 0.57% |
| BlackRock, Inc. | 16,675,173 | 5.57% | $58.20M | +2,434,998 | 0.00% |
| State Street Corp | 11,203,134 | 3.74% | $39.10M | +665,048 | 0.00% |
| Canada Pension Plan Investment Board | 10,218,400 | 3.41% | $35.66M | −3,500 | 0.02% |
| Vanguard Capital Management LLC | 8,375,421 | 2.80% | $29.23M | +940,697 | 0.00% |
| Bank Of America Corp /De/ | 5,748,454 | 1.92% | $20.06M | +2,801,593 | 0.00% |
| Geode Capital Management, LLC | 4,677,959 | 1.56% | $16.33M | +495,986 | 0.00% |
| Marex Group plc | 3,989,100 | 1.33% | $13.92M | −10,000 | 0.06% |
| Marshall Wace, Llp | 2,931,436 | 0.98% | $10.23M | +2,266,979 | 0.01% |
| Alphabet Inc. | 2,812,500 | 0.94% | $9.82M | – | 0.01% |
| Goldman Sachs Group Inc | 2,367,935 | 0.79% | $8.26M | −813,180 | 0.00% |
| Integral Health Asset Management, LLC | 2,000,000 | 0.67% | $6.98M | −1,200,000 | 0.28% |
| Toronto Dominion Bank | 1,972,381 | 0.66% | $6.88M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,881,689 | 0.63% | $6.57M | +174,168 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,868,718 | 0.62% | $6.52M | New | 0.02% |
| Northern Trust Corp | 1,604,084 | 0.54% | $5.60M | +125,233 | 0.00% |
| Charles Schwab Investment Management Inc | 1,379,181 | 0.46% | $4.81M | +13,033 | 0.00% |
| Woodline Partners LP | 1,317,932 | 0.44% | $4.60M | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 185M | 61.7% | 34 / 67 | 65 / 22 | 36M | 15M |
| Q1 2026 | 203 | 164M | 54.9% | 30 / 68 | 57 / 25 | 22M | 7M |
| Q4 2025 | 203 | 160M | 53.4% | 48 / 70 | 47 / 21 | 16M | 22M |
| Q3 2025 | 178 | 166M | 55.4% | 46 / 65 | 37 / 21 | 27M | 7M |
| Q2 2025 | 155 | 146M | 48.8% | 25 / 50 | 48 / 30 | 11M | 15M |
| Q1 2025 | 161 | 149M | 49.9% | 30 / 54 | 41 / 32 | 7M | 15M |
| Q4 2024 | 164 | 158M | 52.8% | 42 / 58 | 33 / 32 | 12M | 8M |
| Q3 2024 | 155 | 154M | 51.5% | 33 / 41 | 45 / 24 | 21M | 5M |
| Q2 2024 | 148 | 149M | 49.9% | 21 / 58 | 37 / 26 | 13M | 14M |
| Q1 2024 | 154 | 150M | 50.2% | 38 / 46 | 40 / 15 | 33M | 9M |
| Q4 2023 | 132 | 126M | 42.2% | 23 / 51 | 31 / 27 | 10M | 11M |
| Q3 2023 | 136 | 128M | 42.6% | 23 / 42 | 39 / 10 | 8M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
140 funds held SANA in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SANA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 10,508,590 | 3.51% | $34.68M | 0.04% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,077,517 | 2.36% | $24.70M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 6,251,644 | 2.09% | $21.82M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,807,959 | 1.61% | $16.78M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 3,106,086 | 1.04% | $10.25M | 0.04% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 2,857,700 | 0.95% | $9.43M | 0.04% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,008,443 | 0.67% | $6.29M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,920,775 | 0.64% | $6.70M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,680,858 | 0.56% | $5.87M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,276,572 | 0.43% | $4.46M | 0.05% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,263,152 | 0.42% | $4.17M | 0.08% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 863,772 | 0.29% | $2.85M | 0.02% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 843,865 | 0.28% | $2.78M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 770,926 | 0.26% | $2.54M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 520,072 | 0.17% | $1.72M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steve Harr | President & CEO, Director | 8,960,751 | 2.99% | Mar 10, 2026 |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 183,352 | 0.06% | Aug 27, 2026 |
| Susan D. Wyrick | See Remarks | 197,241 | 0.07% | Mar 10, 2026 |
| Brian Piper | EVP, Chief Financial Officer | – | – | Feb 18, 2026 |
| Bernard J. Cassidy | EVP & General Counsel | 112,990 | 0.04% | Mar 10, 2025 |
| Hans Edgar Bishop | Director | 5,863,480 | 1.96% | Oct 6, 2026 |
| Robert Nelsen | Director, 10% owner | 10,681,240 | 3.57% | Jun 5, 2026 |
| Michelle Seitz | Director | – | – | Jun 5, 2026 |
| Richard Mulligan | Director | 2,698,121 | 0.90% | Jun 5, 2026 |
| Alise Reicin | Director | – | – | Jun 5, 2026 |
| Patrick Y. Yang | Director | 149,250 | 0.05% | Jun 5, 2026 |
| Joshua H. Bilenker | Director | 20,000 | 0.01% | Jun 5, 2026 |
| Robert L. Rosiello | Director | – | – | Jun 5, 2026 |
| Mary Agnes Wilderotter | Director | 7,106 | 0.00% | Jun 9, 2025 |
| Llc Fmr | 10% owner | 4,707,484 | 1.57% | Jan 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hans Edgar Bishop Director | Oct 5, 2026 | Award | +8,680 | – | – | 5,863,480 |
| Dhavalkumar Dhirajlal Patel EVP, Chief Scientific Officer | Aug 27, 2026 | Tax withholding | −41,158 | $4.11 | $169.16K | 183,352 |
| Dhavalkumar Dhirajlal Patel EVP, Chief Scientific Officer | Aug 26, 2026 | Option exercise | +125,000 | – | – | 224,510 |
| Hans Edgar Bishop Director | Jul 6, 2026 | Award | +6,297 | – | – | 5,854,800 |
| Hans Edgar Bishop Director | Apr 6, 2026 | Award | +7,763 | – | – | 5,848,503 |
| Steve Harr President & CEO, Director | Mar 9, 2026 | Tax withholding | −12,819 | $3.10 | $39.74K | 7,944,251 |
| Steve Harr President & CEO, Director | Mar 9, 2026 | Tax withholding | −11,526 | $3.13 | $36.08K | 7,957,070 |
| Susan D. Wyrick See Remarks | Mar 9, 2026 | Tax withholding | −3,342 | $3.13 | $10.46K | 197,241 |
| Susan D. Wyrick See Remarks | Mar 9, 2026 | Tax withholding | −1,045 | $3.10 | $3.24K | 196,196 |
| Steve Harr President & CEO, Director | Mar 7, 2026 | Option exercise | +50,000 | – | – | 7,968,596 |
| Susan D. Wyrick See Remarks | Mar 7, 2026 | Option exercise | +3,250 | – | – | 200,583 |
| Steve Harr President & CEO, Director | Mar 6, 2026 | Option exercise | +41,666 | – | – | 7,918,596 |
| Susan D. Wyrick See Remarks | Mar 6, 2026 | Option exercise | +10,416 | – | – | 197,333 |
| Susan D. Wyrick See Remarks | Mar 3, 2026 | Tax withholding | −491 | $3.91 | $1.92K | 186,917 |
| Susan D. Wyrick See Remarks | Mar 2, 2026 | Option exercise | +1,525 | – | – | 187,408 |
| Susan D. Wyrick See Remarks | Jan 5, 2026 | Tax withholding | −2,407 | $4.27 | $10.28K | 185,883 |
| Hans Edgar Bishop Director | Jan 5, 2026 | Award | +6,157 | – | – | 5,840,740 |
| Susan D. Wyrick See Remarks | Jan 2, 2026 | Option exercise | +7,500 | – | – | 188,290 |
| Susan D. Wyrick See Remarks | Dec 15, 2025 | Tax withholding | −873 | $5.22 | $4.56K | 180,790 |
| Susan D. Wyrick See Remarks | Dec 13, 2025 | Option exercise | +3,400 | – | – | 181,663 |
| Susan D. Wyrick See Remarks | Dec 4, 2025 | Tax withholding | −2,565 | $4.44 | $11.39K | 178,263 |
| Susan D. Wyrick See Remarks | Dec 3, 2025 | Option exercise | +10,000 | – | – | 180,828 |
| Hans Edgar Bishop Director | Oct 6, 2025 | Award | +5,628 | – | – | 5,834,583 |
| Hans Edgar Bishop Director | Jul 7, 2025 | Award | +7,842 | – | – | 5,828,955 |
| Susan D. Wyrick See Remarks | Jun 4, 2025 | Tax withholding | −2,567 | $2.32 | $5.96K | 167,828 |
| Susan D. Wyrick See Remarks | Jun 3, 2025 | Option exercise | +10,000 | – | – | 170,395 |
| Hans Edgar Bishop Director | Apr 7, 2025 | Award | +16,339 | – | – | 5,821,113 |
| Steve Harr President & CEO, Director | Mar 10, 2025 | Tax withholding | −12,820 | $2.56 | $32.82K | 7,876,930 |
| Susan D. Wyrick See Remarks | Mar 10, 2025 | Tax withholding | −836 | $2.56 | $2.14K | 157,395 |
| Bernard J. Cassidy EVP & General Counsel | Mar 10, 2025 | Tax withholding | −2,833 | $2.56 | $7.25K | 112,990 |
| Steve Harr President & CEO, Director | Mar 7, 2025 | Option exercise | +50,000 | – | – | 7,889,750 |
| Susan D. Wyrick See Remarks | Mar 7, 2025 | Option exercise | +3,250 | – | – | 158,231 |
| Bernard J. Cassidy EVP & General Counsel | Mar 7, 2025 | Option exercise | +11,041 | – | – | 115,823 |
| Susan D. Wyrick See Remarks | Mar 3, 2025 | Tax withholding | −490 | $2.56 | $1.25K | 154,981 |
| Susan D. Wyrick See Remarks | Mar 2, 2025 | Option exercise | +1,525 | – | – | 155,471 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −25,000 | $6.50 | $162.50K | 4,707,423 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −1,000 | $7.26 | $7.26K | 4,541,511 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −164,912 | $6.71 | $1.11M | 4,542,511 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −100,000 | $6.11 | $611.00K | 4,732,423 |
| Hans Edgar Bishop Director | Jan 6, 2025 | Award | +14,285 | – | – | 5,804,774 |
| Susan D. Wyrick See Remarks | Jan 2, 2025 | Tax withholding | −1,566 | $1.65 | $2.58K | 153,946 |
| Susan D. Wyrick See Remarks | Jan 2, 2025 | Option exercise | +5,000 | – | – | 155,512 |
| Hans Edgar Bishop Director | Oct 7, 2024 | Award | +5,938 | – | – | 5,790,489 |
| Richard Mulligan Director | Sep 25, 2024 | Sale(10b5-1 plan) | −150,000 | $3.89 | $583.50K | 2,698,121 |
| Richard Mulligan Director | Sep 24, 2024 | Sale(10b5-1 plan) | −150,000 | $4.08 | $612.00K | 2,848,121 |
| Hans Edgar Bishop Director | Jul 5, 2024 | Award | +4,911 | – | – | 5,784,551 |
| Hans Edgar Bishop Director | Apr 5, 2024 | Award | +2,774 | – | – | 5,779,640 |
| Patrick Y. Yang Director | Mar 8, 2024 | Sale | −25,000 | $9.45 | $236.25K | 149,250 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Mary Agnes Wilderotter Director | Jan 5, 2024 | Award | +1,470 | – | – | 7,106 |
| Hans Edgar Bishop Director | Jan 5, 2024 | Award | +4,901 | – | – | 5,776,866 |
| Christian Hordo EVP, Chief Business Officer | Dec 15, 2023 | Sale(10b5-1 plan) | −75,000 | $4.00 | $300.00K | 867,455 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sana Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 83,223 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christian Hordo & Katharine Hordo Officer | Feb 18, 2025 | 75,000 | $237.00K | Feb 18, 2025 | Founders Shares |
| Christian Hordo & Katharine Hordo Officer | Jan 16, 2025 | 75,000 | $289.50K | Jan 16, 2025 | Founders Shares |
| Christian Hordo & Katharine Hordo Jt Ten Officer | Dec 16, 2024 | 75,000 | $141.75K | Dec 16, 2024 | Founders Shares |
| Nathan Hardy Former CFO | Nov 26, 2024 | 91,607 | $229.02K | Nov 26, 2024 | Founders Stock |
| Nathan Hardy Former CFO | Nov 25, 2024 | 25,933 | $64.96K | Nov 25, 2024 | Founder Stock |
| Nathan Hardy Officer | Oct 21, 2024 | 45,796 | $180.81K | Oct 21, 2024 | Stock Option Exercise |
| Richard Mulligan Director | Sep 25, 2024 | 150,000 | $613.50K | Sep 25, 2024 | Restricted Stock Awards |
| Richard Mulligan Director | Sep 24, 2024 | 150,000 | $613.50K | Sep 24, 2024 | Restricted Stock Awards |
| Christian Hordo & Katharine Hordo Jt Ten Officer | Dec 15, 2023 | 75,000 | $299.25K | Dec 15, 2023 | Restricted Stock Awards |
| Flagship V Venturelabs RX Fund, L.P. Affiliate | Jun 7, 2023 | 39,830 | $254.51K | Jun 7, 2023 | Venture Capital Investment |
| Flagship Ventures Fund V, L.P. Affiliate | Jun 7, 2023 | 310,170 | $1.98M | Jun 7, 2023 | Venture Capital Investment |
| Flagship V Venturelabs RX Fund, L.P. affiliate | May 24, 2023 | 85,334 | $598.19K | May 24, 2023 | venture capital investment |
| Flagship Ventures Fund V, L.P. affiliate | May 24, 2023 | 85,334 | $598.19K | May 24, 2023 | Venture Capital investment |
| Flagship Ventures Fund V, L.P. affiliate | May 24, 2023 | 664,666 | $4.66M | May 24, 2023 | Venture Capital investment |
See a number that looks wrong?